NCT07309848 Hip Fracture Surgery Timing and Blood Transfusion Risk in Patients on DOACs
| NCT ID | NCT07309848 |
| Status | Recruiting |
| Phase | — |
| Sponsor | St. Antonius Hospital |
| Condition | Blood Transfusion |
| Study Type | OBSERVATIONAL |
| Enrollment | 374 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2027-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 374 participants in total. It began in 2025-11-01 with a primary completion date of 2027-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study looks at patients with hip fractures who are taking direct oral anticoagulants (DOACs), a type of blood thinner. In many hospitals, surgery for these patients is delayed because of concerns about bleeding, but waiting longer can also increase risks such as complications and longer hospital stays. The purpose of this study is to find out whether operating within 24 hours is as safe as delaying surgery beyond 24 hours. Specifically, the investigators want to know if early surgery does not lead to a higher need for blood transfusions compared to delayed surgery.
Eligibility Criteria
Inclusion Criteria: * Isolated hip fracture classified as AO/OTA 31A or 31B requiring surgical intervention. * Current DOAC use with the last dose taken ≤24 hours before emergency department (ED) presentation Exclusion Criteria: * Pathologic or periprosthetic hip fractures. * Fracture sustained \>24 hours before ED presentation. * Inter-hospital transfer. * Hematologic disorders (e.g., thalassemia, sickle cell disease, aplastic anemia, myelodysplastic syndromes, leukemia). * Use of a non-EMA-approved DOAC (e.g., betrixaban).
Contact & Investigator
Henk Jan Schuijt, MD, PhD
PRINCIPAL INVESTIGATOR
Amsterdam University Medical Center
Frequently Asked Questions
Who can join the NCT07309848 clinical trial?
This trial is open to participants of all sexes, studying Blood Transfusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07309848 currently recruiting?
Yes, NCT07309848 is actively recruiting participants. Contact the research team at t.schiepers@antoniusziekenhuis.nl for enrollment information.
Where is the NCT07309848 trial being conducted?
This trial is being conducted at Almelo, Netherlands, Amsterdam, Netherlands, Arnhem, Netherlands, Deventer, Netherlands and 3 additional locations.
Who is sponsoring the NCT07309848 clinical trial?
NCT07309848 is sponsored by St. Antonius Hospital. The principal investigator is Henk Jan Schuijt, MD, PhD at Amsterdam University Medical Center. The trial plans to enroll 374 participants.